Why the study?
Does optimal antithrombotic therapy reduce thrombus burden assessed by serial FD-OCT in patients with highly thrombotic ACS?
Observational (n=16)
Does optimal antithrombotic therapy reduce thrombus burden assessed by serial FD-OCT in patients with highly thrombotic ACS?
Serial FD-OCT assessment is feasible and safe for monitoring in vivo clot regression in selected ACS patients treated with a deferred stenting strategy.
Serial OCT thrombus monitoring is feasible in selected ACS cases with deferred stenting; leaves open whether this strategy improves outcomes.
AIMS: We investigated the feasibility of thrombus quantification by frequency-domain optical coherence tomography (FD-OCT) methods in patients with highly thrombotic acute coronary syndrome (ACS) treated by deferred stenting strategy. METHODS AND RESULTS: Patients were suitable for inclusion if they presented (i) an ACS that was successfully revascularized by manual thrombo-aspiration and (ii) a large residual thrombus on coronary angiography and initial FD-OCT analysis. These patients underwent a second procedure including FD-OCT analysis after several days of optimal antithrombotic therapy. Serial area measurements within the athero-thrombotic culprit lesion were performed to evaluate the OCT-thrombus score, volume, and length. Sixteen patients (88% men/age = 59.3 ± 4.1 years/94% STEMI) were included in the study. The mean delay between OCT analyses was 3.9 ± 0.3 day. No adverse event was observed during this interval. We observed a reduction of thrombus burden between the two analyses, as assessed by the significant reductions in OCT-thrombus score (22.3 ± 2.6 vs. 10.3 ± 1.3, P < 0.001), OCT-thrombus volume (9.6 ± 2.3 vs. 3.6 ± 0.9 mm(3), P = 0.003), and OCT-thrombus length (11.1 ± 1.4 vs. 7.4 ± 0.8 mm, P = 0.01). The percentages of OCT-thrombus score and volume reduction were highly correlated with the inter-OCT analyses delay (respectively ρ = 0.65 and ρ = 0.84, P < 0.01 for both). CONCLUSION: FD-OCT assessment of thrombus volume in selected ACS patients is feasible, safe, and could allow clot regression monitoring in vivo.
No takes yet. Share an insight, caveat, or question.
Amabile et al. (2014) conducted an observational in Acute coronary syndrome (n=16). Deferred stenting with optimal antithrombotic therapy vs. Baseline was evaluated on OCT-thrombus score (p=<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: